BOSTON, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq ... target patient population (KRAS-mutated pancreatic adenocarcinoma) and the primary study endpoint of disease ...
(“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the ...
("Silexion Therapeutics” or the "Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the ...
(“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced ...
(“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive ...
The recent advancements described in patent applications WO 2024/243186 A2 and WO 2024/246099 A1 introduce two novel classes of inhibitors: heterocyclic compounds targeting NRAS G12D and spirocyclic ...
SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles reduced tumor cell numbers by ~3-fold, tumor area by ~1 ...
On Tuesday, Silexion Therapeutics Corp. (NASDAQ ... SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles ...
The company is exploring how this promising data can inform an expanded next-generation treatment strategy for KRAS-driven cancers. It expects to announce details of its expanded development plan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback